Engineered immune cells take aim at deadly lung cancer
NCT ID NCT07509034
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 34 times
Summary
This early-phase trial tests a new therapy for people with advanced small cell lung cancer or similar neuroendocrine cancers that have not responded to prior treatment. The approach involves collecting a patient's own immune cells, modifying them in a lab to recognize a protein called B7-H3 found on cancer cells, and infusing them back into the body. The study will enroll 40 participants to evaluate safety and determine the best dose, with follow-up lasting up to 15 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- B7-H3 CAR T cells (a type of immune cell therapy)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced small cell lung cancer or similar cancers that have stopped responding to standard therapy.
- What could go wrong
- This is an early phase 1 trial with only 40 participants, so it is primarily testing safety. The treatment may not shrink tumors, and there are risks from chemotherapy and potential side effects from the modified cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can engineered immune cells target a common ovarian cancer protein?
- Can a new imaging tracer outperform standard scans in finding hidden tumors?
- Can a Two-Drug attack shrink tough lung cancers?
- Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining